.png){kind=icon}
.png){kind=icon}
Return
Synthetic Biology-Driven Innovations in Triple-Negative Breast Cancer: Integrating Engineering Design with Targeted Therapeutics
.png){kind=icon}
PRE
AI
N
M
S
E
Z
N
M
S
V
DOI：10.1016/j.jbiotec.2026.04.017.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Synthetic biology offers innovative solutions for TNBC, integrating engineered cells, gene-editing tools, and programmable microbes to overcome therapeutic limitations. • Logic-gated CAR-T cells improve tumor specificity and safety, representing a major advancement in cell-based immunotherapy for TNBC. • Engineered bacterial therapies demonstrate selective tumor targeting and significant antitumor activity in preclinical TNBC models. • iPSC-based platforms support patient-specific TNBC modeling and the generation of immune effectors like CAR-NK cells. • CRISPR/Cas9 technology enables precise editing of oncogenic drivers and resistance pathways, enhancing targeted TNBC therapy.
Keywords:
Synthetic biology
Triple-negative breast cancer
CAR-T cells
Engineered bacteria
CRISPR/Cas9
Journal
IF:
3.9
Papers:
1.5W
Citations:
1.5W
Organization
Cited Papers